Tag: macular degeneration treatment market forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Macular Degeneration Treatment Market?

The macular degeneration treatment market has experienced rapid expansion recently. Forecasts indicate its expansion from $11.05 billion in 2024 to $12.38 billion in 2025, driven by a compound annual growth rate (CAGR) of 12.0%. This historical growth is largely attributable to factors including an aging population, lifestyle changes, limited treatment options, rising awareness, and the development of healthcare infrastructure.

The macular degeneration treatment market size is anticipated to experience significant expansion over the next few years, reaching $18.87 billion by 2029 with a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is propelled by factors such as advancements in research, increased healthcare expenditure, rising incidence rates, the adoption of personalized medicine approaches, and global initiatives for vision health. Prominent trends in the same period encompass an emphasis on neuroprotection and regeneration therapies, the broadening of telemedicine and remote monitoring, continued application of personalized medicine strategies, the investigation of stem cell therapies, and patient-focused programs for awareness and education.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

What Are The Top Growth Drivers Impacting The Macular Degeneration Treatment Market Outlook?

The escalating prevalence of retinal disorders is anticipated to stimulate the expansion of the macular degeneration treatment market. These conditions damage vital retinal tissue and interfere with how individuals process visual information, resulting in impaired or absent vision. For example, the American Academy of Ophthalmology projects that by 2050, around 7.32 million people in the United States will suffer from primary open-angle glaucoma, a broad category encompassing various eye disorders, with the highest proportions observed in populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The most significant demographic within this group is Hispanic men. Thus, the rising burden of retinal disorders is propelling the growth of the macular degeneration treatment market.

What Are The Key Segments In The Macular Degeneration Treatment Market?

The macular degeneration treatmentmarket covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD

2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals

3) By Route of Administration: Oral; Injectable; Other Route of Administration

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements; Lifestyle Modification Treatments

2) By Intermediate AMD: Anti-VEGF Injections; Photodynamic Therapy

3) By Late-Stage AMD: Surgical Treatments; Advanced Anti-VEGF Therapies; Gene Therapy Options

How Are Emerging Market Trends Shaping The Macular Degeneration Treatment Industry Landscape?

Leading firms within the macular degeneration treatment market are prioritizing the creation of biosimilars aimed at managing age-related macular degeneration (AMD), thereby enhancing access to successful treatments. These biosimilars are biological medical products that exhibit strong resemblance to an existing approved reference product, displaying no significant clinical distinctions regarding safety, purity, or potency. An example of this trend occurred in May 2024, when Biocon Biologics Ltd, based in India, and Samsung Bioepis Co. Ltd, a South Korea-based enterprise, secured FDA Approvals for their new biosimilars, Yesafili and Opuviz. Both of these biosimilars work by inhibiting vascular endothelial growth factor (VEGF), a protein known to cause atypical blood vessel proliferation in the eye. This mechanism is crucial for preventing the loss of vision linked to conditions such as AMD and diabetic retinopathy. The FDA’s rigorous approval methodology incorporated comparative research, which demonstrated that Yesafili and Opuviz possess equivalent efficacy and safety profiles when benchmarked against Eylea. These assessments thoroughly evaluated the pharmacokinetics and immunogenicity of the biosimilars.

Which Leading Players Are Enhancing Their Macular Degeneration Treatment Market Presence Worldwide?

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Which Regional Markets Are Contributing Most To The Macular Degeneration Treatment Industry Expansion?

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Macular Degeneration Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

Browse Through More Reports Similar to the Global Macular Degeneration Treatment Market 2025, By The Business Research Company

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Gastrointestinal Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Medical Equipment Maintenance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-equipment-maintenance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Macular Degeneration Treatment Market Grown from 2024 to 2025?

The market for macular degeneration treatment has seen significant growth in previous years. The expansion is expected to continue, with market size predicted to increase from $11.05 billion in 2024 to $12.42 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.4%. Several factors contribute to the growth witnessed during the historic period, including an aging population, changes in lifestyle, scarcity of treatment alternatives, heightened awareness, and improvements in healthcare infrastructure.

What Growth Rate Is Anticipated for the Macular Degeneration Treatment Market in the Coming Years?

The market for treatments for macular degeneration is projected to experience swift expansion in the coming years, with an estimated value of $19.06 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth during the forecast period can be credited to advancements in scientific research, an increase in healthcare spending, escalating incidence rates, customized medicinal treatments, and worldwide initiatives toward vision health. Key trends for this period encompass focus on neuroprotective and regenerative treatments, the broadening of telemedicine and distance monitoring, personalization in medicine, exploration of stem cell therapies, and patient-centric initiatives for increasing awareness and education.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

Who Are the Leading Companies in the Macular Degeneration Treatment Market?

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

What Are the Key Drivers of the Macular Degeneration Treatment Market?

The macular degeneration treatment market is projected to grow owing to the escalating prevalence of retinal disorders. These disorders can impair the essential tissue and disrupt how visual data is processed, resulting in either warped or non-existent vision. As an example, the American Academy of Ophthalmology has forecasted that by 2050, roughly 7.32 million U.S citizens will be suffering from primary open-angle glaucoma, a broad term for a range of eye-related conditions. The majority of those affected will be those between the ages of 70 and 79 (32%), women (50%), and Hispanics (50%); the most substantial demographic portion being Hispanic males. Hence, the surge in retinal disorders incidence is fueling the expansion of the macular degeneration treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

What Are the Key Market Segments in the Macular Degeneration Treatment Industry?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

3) By Route of Administration: Oral, Injectable, Other Route of Administration

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

What Are the Latest Trends in the Macular Degeneration Treatment Market?

Key firms engaged in the macular degeneration treatment industry are focusing on creating biosimilars to treat age-related macular degeneration (AMD) in order to enhance access to effective treatment. Biosimilars are biological medication products that are almost identical to an already approved reference product, and there are no clinically significant differences related to safety, purity, or potency. For instance, Biocon Biologics Ltd, an Indian company, and Samsung Bioepis Co. Ltd, from South Korea, received FDA approvals for Yesafili and Opuviz, two new biosimilars, in May 2024. The biosimilars both block vascular endothelial growth factor (VEGF), which causes unusual blood vessel growth in the eye, thereby preventing vision loss linked to conditions like AMD and diabetic retinopathy. The approval process by the FDA included comparative analysis that showed no notable differences in efficacy or safety between Yesafili and Opuviz compared to Eylea. Such studies conducted thorough examinations of the biosimilars’ pharmacokinetics and immunogenicity.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What Are the Key Regional Markets in the Macular Degeneration Treatment Industry?

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799

This Report Delivers Insight On:

1. How big is the macular degeneration treatment market, and how is it changing globally?

2. Who are the major companies in the macular degeneration treatment market, and how are they performing?

3. What are the key opportunities and risks in the macular degeneration treatment market right now?

4. Which products or customer segments are growing the most in the macular degeneration treatment market?

5. What factors are helping or slowing down the growth of the macular degeneration treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the macular degeneration treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Macular Degeneration Treatment Market Through 2034?#_x000D_

The market for macular degeneration treatment has seen a significant expansion in recent years. Its size is projected to increase from $11.05 billion in 2024 to $12.42 billion in 2025, experiencing a compound annual growth rate (CAGR) of 12.4%. Factors contributing to this growth in the historical period include an increase in the elderly population, lifestyle alterations, few treatment choices, heightened awareness, and the advancement of healthcare infrastructure._x000D_

_x000D_

The market for treatments of macular degeneration is predicted to experience swift expansion in the coming years. The market is projected to increase to $19.06 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. The upswing during this forecast period can be linked to progress in research, escalated spending on healthcare, rising incident rates, customized medical treatments, and global movements for eye health. Significant trends during the forecast timeframe include an emphasis on neuroprotection and regeneration therapies, the growth of telemedicine and remote monitoring, personalized medical treatments, exploration of stem cell therapies, and patient-centered initiatives for awareness and schooling._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp_x000D_

_x000D_

#What Are the Core Growth Drivers Propelling the Macular Degeneration Treatment Market Forward?#_x000D_

The escalating impact of retinal disorders is anticipated to drive the expansion of the macular degeneration treatment market. These disorders damage crucial tissue and disrupt how individuals process visual data, causing blurred or missing vision. For example, the American Academy of Ophthalmology predicts that 7.32 million people in the United States will suffer from primary open-angle glaucoma by 2050. This term includes a range of eye conditions, and the largest prevalence is expected within groups aged 70-79 years (32%), women (50%), and Hispanics (50%). The biggest demographic within this is Hispanic men. As such, the rising impact of retinal disorders is fueling the development of the macular degeneration treatment market._x000D_

_x000D_

#What Segment Types Define the Macular Degeneration Treatment Market Structure?#_x000D_

The macular degeneration treatment market covered in this report is segmented –_x000D_

_x000D_

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD_x000D_

2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals_x000D_

3) By Route of Administration: Oral, Injectable, Other Route of Administration_x000D_

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration_x000D_

_x000D_

Subsegments:_x000D_

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments_x000D_

2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy_x000D_

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Macular Degeneration Treatment Market?#_x000D_

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Emerging Trends that Are Influencing theMacular Degeneration Treatment Industry Evolution?#_x000D_

Leading corporations in the realm of the macular degeneration treatment marketplace are concentrating on the creation of biosimilars for the treatment of age-related macular degeneration (AMD). These biosimilars, biological medicinal substances very akin to already approved reference products, do not demonstrate any clinically significant differences in their safety, purity, or potency. For instance, approaching May 2024, Biocon Biologics Ltd, indigenous to India, and Samsung Bioepis Co. Ltd, a company from South Korea, earned FDA Approvals for two novel biosimilars, namely Yesafili and Opuviz. Designed to inhibit the vascular endothelial growth factor (VEGF) responsible for irregular blood vessel growth in the eye, these biosimilars prevent the vision loss that conditions like AMD and diabetic retinopathy can cause. The FDA granted approval for these biosimilars following comparative studies that evidenced no notable differences between the efficacy or safety of Yesafili and Opuviz, as compared to Eylea. These tests included meticulous evaluations of the biosimilars’ pharmacokinetics and immunogenicity._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report_x000D_

_x000D_

#What Is the Definition of the Macular Degeneration Treatment Market?#_x000D_

Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Macular Degeneration Treatment Market?

The escalating prevalence of retinal disorders is predicted to fuel the expansion of the macular degeneration treatment market. These disorders harm the critical tissue that manages how we perceive visual data, resulting in absent or distorted vision. For example, the American Academy of Ophthalmology predicts that by 2050, around 7.32 million individuals in the United States will suffer from primary open-angle glaucoma. This term encompasses a variety of eye diseases and is most prevalent in individuals between 70 to 79 years old (32%), women (50%), and Hispanics (50%). The most significant demographic group being Hispanic men. Therefore, the growing occurrence of retinal disorders is a key driver for the development of the macular degeneration treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

#What Long-Term Growth Rate is Expected for theMacular Degeneration Treatment Market Between 2025 and 2034?

Over the past few years, the market size for the treatment of macular degeneration has seen a swift expansion. The growth is projected to continue, rising from $11.05 billion in 2024 to an estimated $12.42 billion in 2025, which demonstrates a compound annual growth rate (CAGR) of 12.4%. Factors contributing to this increase during the historic period include an aging population, shifts in lifestyle, a scarcity of treatment alternatives, heightening awareness, and infrastructural advancements in the healthcare sector.

In the coming years, the market size for macular degeneration treatment is projected to experience significant growth. The market is estimated to reach a value of $19.06 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. This growth during the forecast period is likely due to advancements in research, higher healthcare spending, increased incidence rates, personalized medicine strategies, and worldwide initiatives for vision health. Key trends anticipated during this period include emphasis on neuroprotection and regenerative therapies, the proliferation of telemedicine and remote patient monitoring, personalized medicine strategies, exploration of stem cell therapies, and patient-oriented initiatives for promoting awareness and education.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799

What New Market Trends Are Reshaping theMacular Degeneration Treatment Market and Its Opportunities?

Top corporations in the macular degeneration treatment market are honing their focus on creating biosimilars for the treatment of age-related macular degeneration (AMD) with the intent of improving access to potent therapies. Biosimilars are essentially biological medical products that share a high degree of similarity to a pre-existing approved reference solution, but with no significant differences in safety, purity, or effectiveness. For example, in May 2024, Biocon Biologics Ltd, an India-based business, as well as Samsung Bioepis Co. Ltd, situated in South Korea, gained FDA approvals for their new biosimilars, Yesafili and Opuviz. These biosimilars hinder vascular endothelial growth factor (VEGF), a key player in the abnormal growth of blood vessels in the eye. With this interference, vision loss can be prevented in diseases like AMD and diabetic retinopathy. The FDA approved Yesafili and Opuviz after comparative studies revealed their efficacy and safety level were on par with Eylea. This approval process included vigorous evaluation of the biosimilars with respect to pharmacokinetics and immunogenicity.

Who Are the Leading Market Players Fueling Growth in the Macular Degeneration Treatment Market Trend?

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

How is the Global Macular Degeneration Treatment Market Segemented?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

3) By Route of Administration: Oral, Injectable, Other Route of Administration

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

Which Geographics are Influencing the Growth of the Macular Degeneration Treatment Market?

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Macular Degeneration Treatment Market 2025, By The Business Research Company:

Cutting Tool And Machine Tool Accessory Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cutting-tool-and-machine-tool-accessory-global-market-report

Metal Valve Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/metal-valve-global-market-report

Stamped Metal Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/stamped-metal-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the macular degeneration treatment market grown over the years?

Recent years have seen a rapid expansion in the market size for macular degeneration treatment. Projected growth indicates that the market will increase from $11.05 billion in 2024 to $12.42 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.4%. Factors contributing to growth during the historical period include an aging population, changes in lifestyle, limited treatment availability, heightened awareness, and the development of healthcare infrastructure.

What Is the forecasted market size and growth rate for the macular degeneration treatment market?

Get your macular degeneration treatment market report here!

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What are the major factors driving growth in the macular degeneration treatment market?

The rising prevalence of retinal diseases is anticipated to boost the macular degeneration treatment market’s progress. These eye-related conditions adversely influence the crucial tissue pivotal for visual information processing, resulting in distorted or completely missing vision. As an illustrative example, data from the American Academy of Ophthalmology indicates that by the time we get to 2050, an approximation of 7.32 million US residents will be diagnosed with primary open-angle glaucoma, an umbrella term for a collective of eye diseases. The highest rates will be seen among individuals aged between 70 to 79 years (32%), females (50%), and Hispanics (50%), with Hispanic men making up the majority demographic. This amplifying occurrence of retinal ailments is consequently fuelling the expansion of the macular degeneration treatment market.

What key areas define the segmentation of the global macular degeneration treatment Market?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

3) By Route of Administration: Oral, Injectable, Other Route of Administration

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

What are the top market players propelling the growth of the macular degeneration treatment industry?

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

What are the key trends shaping the future of the macular degeneration treatment market?

A variety of prominent enterprises in the macular degeneration treatment business include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799

What regions are dominating the macular degeneration treatment market growth?

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Gastrointestinal Bleeding Treatment Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Hemodialysis And Peritoneal Dialysis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hemodialysis-and-peritoneal-dialysis-global-market-report

Endoscopy Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/endoscopy-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Machinery Market From 2025 to 2034?

The market for macular degeneration treatment has rapidly expanded over the past few years. A leap from $11.05 billion in 2024 to $12.42 billion in 2025 is anticipated, reflecting a compound annual growth rate (CAGR) of 12.4%. The past years’ growth can be linked to factors such as an aging population, lifestyle upheavals, few available therapies, increasing awareness, and advancements in healthcare infrastructure.

Expectations are high for the macular degeneration treatment market, as it is poised to experience significant expansion in the coming years. The market is projected to reach $19.06 billion by 2029, boasting a compound annual growth rate (CAGR) of 11.3%. This impressive rise over the forecast period can be attributed to a multitude of factors. These include enhancements in research, an uptick in healthcare spending, an increased frequency of incidence rates, personalized treatment strategies, and worldwide commitment to visual health. Foreseen trends for the allocation period encompass emphasis on neuroprotection and regenerative therapies, the growth of telemedicine and remote patient monitoring, personalized medicine methodologies, exploration of stem cell treatments, and patient-centered initiatives aimed at boosting awareness and education.

How Are the key drivers Contributing to the Expansion of the Market?

The macular degeneration treatment market is anticipated to expand due to the escalating prevalence of retinal disorders. These disorders, which affect the crucial tissue involved in processing visual information, can result in distorted or even a total loss of vision. For example, the American Academy of Ophthalmology has predicted that by the year 2050, about 7.32 million individuals in the United States will be diagnosed with primary open-angle glaucoma. This term refers to a set of eye disorders most prevalent among those aged 70 to 79 years (32%), women (50%), and Hispanics (50%), with the largest demographic group being Hispanic men. Consequently, the rising prevalence of retinal disorders is fuelling the advancement of the macular degeneration treatment market.

Get Your Free Sample of the Global Machinery Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

What Are the Key Industry Players Leading the Charge in the Machinery Market’s Growth?

Major companies operating in the macular degeneration treatment market include:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche Ltd._x000D_

• Allergan Inc._x000D_

• Bayer AG_x000D_

• Novartis AG_x000D_

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Machinery Market?

Leading companies in the market for macular degeneration therapy are concentrating their efforts on forming biosimilars to treat age-related macular degeneration (AMD) to improve access to effective treatments. Biosimilars are bio-medical products that bear a high resemblance to an already accepted reference product, maintaining similar levels of safety, purity, or effectiveness clinically. For example, in May of 2024, Biocon Biologics Ltd from India and Samsung Bioepis Co. Ltd from South Korea, got FDA authorization for two new biosimilars, Yesafili and Opuviz. Both biosimilars obstruct the action of vascular endothelial growth factor (VEGF), the cause behind unusual blood vessel growth in the eye. This prevention aids in averting vision loss linked with conditions such as AMD and diabetic retinopathy. The FDA approved these after conducting comparative investigations demonstrating that Yesafili and Opuviz maintain efficacy and safety levels on par with Eylea. This approval process was thorough and checked the pharmacokinetics and immunogenicity of the biosimilars.

Secure Your Global Machinery Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What Are the Core Segments of the Machinery Market, and How Do They Contribute to Growth?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

3) By Route of Administration: Oral, Injectable, Other Route of Administration

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

What Regions Are Influencing the Dynamics of the Machinery Market?

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Elements Shape the Definition of the Machinery Market?

Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision.

Browse Through More Similar Reports By The Business Research Company:

Gastrointestinal Bleeding Treatment Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Hemodialysis And Peritoneal Dialysis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hemodialysis-and-peritoneal-dialysis-global-market-report

Endoscopy Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/endoscopy-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: